Reynaldo Narag
Internal Medicine · Fallon, NVNPI 1598747156
Payments from drug & device makers
Across 151 payments — averaging $14.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$340
- AbbVie$327
- GSK$322
- AstraZeneca$275
- Boehringer Ingelheim$196
- Novo Nordisk$179
- plus $523 from 15 others
What the payments were for
- Food & beverage$2,162100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 24 | $340 |
| AbbVie(2 entities) | 23 | $327 |
| GSK | 28 | $322 |
| AstraZeneca | 18 | $275 |
| Boehringer Ingelheim | 13 | $196 |
| Novo Nordisk | 12 | $179 |
| Eisai Inc. | 5 | $74 |
| Sanofi-aventis U.S. LLC | 5 | $62 |
| Abbott | 3 | $57 |
| Bayer | 3 | $46 |
| Astellas Pharma US Inc | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $38 |
| Amgen | 2 | $37 |
| Merck | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $14 |
How this compares
$2,162 in reported general payments places this provider in the 80th percentile of 1,071 internal medicine providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $14,023 |
| EliquisApixaban | 12 | $13,088 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,237 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,349 |
| SynthroidLevothyroxine Sodium | 14 | $1,150 |
| Atorvastatin Calcium | 41 | $934 |
| Rosuvastatin Calcium | 58 | $888 |
| Omeprazole | 50 | $649 |
| Hydroxyzine Hcl | 20 | $597 |
| Lisinopril | 79 | $518 |
| Potassium Chloride | 24 | $475 |
| Gabapentin | 34 | $468 |
| Levothyroxine Sodium | 50 | $417 |
| Tizanidine Hcl | 23 | $353 |
| Amlodipine Besylate | 49 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $179 | $14,02314 claims |
| PfizerEliquis | $340 | $13,08812 claims |
| AbbVieSynthroid | $327 | $1,15014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,071 internal medicine providers in Nevada.
Other internal medicine in Fallon
- Darin BrimhallLas Vegas$39.7M
- Alton WaltersLas Vegas$8.9M
- Michael JacobsLas Vegas$8.1M
- Nirupa PaulrajLas Vegas$5.8M
- Atoya AdamsLas Vegas$5.4M
- Roger EstevezLas Vegas$3.7M
- Syed PervaizLas Vegas$3.1M
- Marigene Salazar SharmaHenderson$2.5M
- Mavis MatsumotoHenderson$1.8M
- Vrijendra HoonLas Vegas$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.